Predictors of hepatitis C treatment response: what's new?

被引：4

作者：

Berry, Louise ^{[1
]}

Irving, Will ^{[2
]}

机构：

[1] Nottingham Univ Hosp NHS Trust, Dept Microbiol, Nottingham NG7 2UH, England

[2] Univ Nottingham, NIHR Biomed Res Unit Gastroenterol & Liver, Nottingham NG7 2UH, England

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2014年 / 12卷 / 02期

关键词：

direct-acting antivirals; hepatitis C virus; IL-28B; interferon; predictors; ribavirin; sustained virological response; SUSTAINED VIROLOGICAL RESPONSE; EARLY VIRAL KINETICS; PEGINTERFERON ALPHA-2A; PEGYLATED INTERFERON; COMBINATION THERAPY; GENETIC-VARIATION; VIRUS-INFECTION; PLUS RIBAVIRIN; IL28B GENOTYPE; TELAPREVIR;

D O I：

10.1586/14787210.2014.874283

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Hepatitis C virus infection is a growing, global health problem, with mortality expected to reach a peak in the next ten years in many western countries. A number of host and viral factors have been established as useful predictors of treatment response in the context of interferon and ribavirin. Several new markers have recently been identified that improve our understanding of treatment response. The addition of protease inhibitors to treatment regimens has highlighted the importance of viral kinetics on-treatment in predicting response to treatment. Many new classes of direct acting anti-virals are currently being developed and expected to be clinically available in the near future. Current predictors of treatment response will be redefined in the context of interferon free regimens.

引用

页码：183 / 191

页数：9

共 64 条

[1] 1α,25-Dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in Human Monocytes [J].

Almerighi, Cristiana ;

Sinistro, Anna ;

Cavazza, Antonella ;

Ciaprini, Chiara ;

Rocchi, Giovanni ;

Bergamini, Alberto .

CYTOKINE, 2009, 45 (03) :190-197

[2] Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].

Alter, HJ ;

Seeff, LB .

SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35

[3] The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report [J].

Antaki, Nabil ;

Craxi, Antonio ;

Kamal, Sanaa ;

Moucari, Rami ;

Van der Merwe, Schalk ;

Haffar, Samir ;

Gadano, Adrian ;

Zein, Nizar ;

Lai, Ching Lung ;

Pawlotsky, Jean-Michel ;

Heathcote, E. Jenny ;

Dusheiko, Geoffrey ;

Marcellin, Patrick .

LIVER INTERNATIONAL, 2010, 30 (03) :342-355

[4]

Arnaud C, 2013, ANTIVIR THER

[5] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[6] The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients [J].

Baur, Katharina ;

Mertens, Joachim C. ;

Schmitt, Johannes ;

Iwata, Rika ;

Stieger, Bruno ;

Frei, Pascal ;

Seifert, Burkhardt ;

Ferrari, Heike A. Bischoff ;

von Eckardstein, Arnold ;

Muellhaupt, Beat ;

Geier, Andreas .

ANTIVIRAL THERAPY, 2012, 17 (03) :541-547

[7] Individualized Treatment Strategy According to Early Viral Kinetics in Hepatitis C Virus Type 1-Infected Patients [J].

Berg, Thomas ;

Weich, Viola ;

Teuber, Gerlinde ;

Klinker, Hartwig ;

Moeller, Bernd ;

Rasenack, Jens ;

Hinrichsen, Holger ;

Gerlach, Tilman ;

Spengler, Ulrich ;

Buggisch, Peter ;

Balk, Heike ;

Zankel, Mygra ;

Neumann, Konrad ;

Sarrazin, Christoph ;

Zeuzem, Stefan .

HEPATOLOGY, 2009, 50 (02) :369-377

[8] Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs 16-week delayed ribavirin [J].

Bräu, N ;

Rodriguez-Torres, M ;

Prokupek, D ;

Bonacini, M ;

Giffen, CA ;

Smith, JJ ;

Frost, KR ;

Kostman, JR .

HEPATOLOGY, 2004, 39 (04) :989-998

[9] Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:: an evidence-based approach [J].

Cammà, C ;

Giunta, M ;

Andreone, P ;

Craxì, A .

JOURNAL OF HEPATOLOGY, 2001, 34 (04) :593-602

[10] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].

Carrat, F ;

Bani-Sadr, F ;

Pol, S ;

Rosenthal, E ;

Lunel-Fabiani, F ;

Benzekri, A ;

Morand, P ;

Goujard, C ;

Pialoux, G ;

Piroth, L ;

Salmon-Céron, D ;

Degott, C ;

Cacoub, P ;

Perronne, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848

← 1 2 3 4 5 6 7 →